Tecan Group's earnings have been declining at an average annual rate of -25.5%, while the Life Sciences industry saw earnings declining at 3.8% annually. Revenues have been growing at an average rate of 0.9% per year.
Key information
-25.46%
Earnings growth rate
-26.64%
EPS growth rate
Life Sciences Industry Growth
21.51%
Revenue growth rate
0.88%
Return on equity
-9.61%
Net Margin
-12.54%
Next Earnings Update
11 Aug 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tecan Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:TCHB.F Revenue, expenses and earnings (CHF Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
882
-111
200
67
30 Sep 25
895
-24
191
66
30 Jun 25
907
63
182
71
31 Mar 25
920
65
183
70
31 Dec 24
934
68
184
63
30 Sep 24
967
85
188
63
30 Jun 24
1,000
101
192
64
31 Mar 24
1,037
117
192
67
31 Dec 23
1,074
132
192
70
30 Sep 23
1,088
120
198
74
30 Jun 23
1,102
109
205
78
31 Mar 23
1,123
115
209
78
31 Dec 22
1,144
121
214
78
30 Sep 22
1,110
113
212
79
30 Jun 22
1,077
105
210
79
31 Mar 22
1,012
113
201
76
31 Dec 21
947
122
192
72
30 Sep 21
911
136
192
70
30 Jun 21
875
150
191
68
31 Mar 21
803
127
182
65
31 Dec 20
731
104
172
62
30 Sep 20
691
94
160
59
30 Jun 20
651
84
149
56
31 Mar 20
644
79
149
58
31 Dec 19
637
73
149
60
30 Sep 19
627
70
150
59
30 Jun 19
616
67
151
59
31 Mar 19
605
69
146
55
31 Dec 18
594
71
141
51
30 Sep 18
582
70
139
50
30 Jun 18
570
69
138
49
31 Mar 18
559
67
137
50
31 Dec 17
549
66
136
50
30 Sep 17
536
62
132
49
30 Jun 17
523
57
129
48
31 Mar 17
515
56
127
47
31 Dec 16
506
55
125
47
30 Sep 16
491
55
123
45
30 Jun 16
476
55
120
43
31 Mar 16
458
56
115
41
31 Dec 15
440
57
110
40
30 Sep 15
434
52
108
41
30 Jun 15
427
48
106
42
Quality Earnings: TCHB.F is currently unprofitable.
Growing Profit Margin: TCHB.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCHB.F is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare TCHB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCHB.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (3.8%).
Return on Equity
High ROE: TCHB.F has a negative Return on Equity (-9.61%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/08 07:15
End of Day Share Price
2026/04/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.